Astellas Pharma Inc.
Japanese multinational pharmaceutical company formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical; specializes in oncology, urology, immunology, cardiology, and infectious disease treatments.
Clinical Trials
577
22 active
Approvals
28
Total approvals
Agencies
2
Regulatory bodies
Founded
2005
Active, not recruiting
21
3.6%
Completed
509
88.2%
Not yet recruiting
1
0.2%
Recruiting
9
1.6%
Terminated
32
5.5%
Withdrawn
5
0.9%
- The CHMP has adopted a positive opinion recommending enfortumab vedotin plus pembrolizumab as neoadjuvant and adjuvant treatment for adults with resectable muscle-invasive bladder cancer in the EU. - The opinion rests on Phase 3 EV-304 data showing a 47% reduction in risk of recurrence, progression or death and a 35% reduction in risk of death versus gemcitabine-cisplatin. - If the European Commission approves, the MIBC indication would extend from cisplatin-ineligible patients to all adults with resectable disease regardless of cisplatin eligibility.
- Lupin expects biosimilar turnover of close to $500 million over the next five years, anchored by its recently approved pegfilgrastim biosimilar and upcoming ranibizumab launches. - The company has invested about ₹500 crore in biosimilar manufacturing capacity and plans to raise total investment to roughly ₹700 crore. - Lupin has begun raising external funding for Kaveri Therapeutics, its oncology-focused spin-off housing two specialised oncology programmes, while intending to remain majority shareholder. - Biosimilars of nivolumab, dinutuzumab and pertuzumab are planned for India, alongside existing etanercept biosimilar sales in Europe and Japan through partnerships.
- Olema Oncology has appointed Jason O'Byrne, MBA, as Chief Financial Officer as the company approaches pivotal data from its OPERA-01 study and a potential first commercial launch. - O'Byrne joins from Vir Biotechnology, where he served as Executive Vice President and CFO, and previously held CFO roles at Caribou Biosciences and Audentes Therapeutics. - His background spans corporate strategy, capital markets, business development, and financial management, including leadership of Caribou's IPO and the $3 billion Astellas acquisition of Audentes. - Olema highlighted its strong balance sheet as it advances palazestrant (OP-1250) and OP-3136 toward multiple upcoming milestones in breast cancer and beyond.
- Russia's Health Ministry has authorized domestic drugmaker Ammedart to conduct bioequivalence trials of a generic version of Astellas' Xospata (gilteritinib) for acute myeloid leukaemia. - The trial will enroll 100 healthy volunteers at the Yaroslavl Regional Clinical Narcological Hospital, with authorization valid until the end of 2026. - Xospata is indicated as monotherapy for adults with relapsed AML carrying an FLT3 mutation and holds orphan status, ranking among Russia's most expensive state-procured drugs. - Between January and August 2025, 326 packs were procured through government purchases totaling 631.3 million roubles, at a weighted average cost of 1.9 million roubles per pack.
- At ASRS 2026 in Montreal, durable treatment strategies for wet AMD dominated research, with gene therapy, intravitreal implant and optogenetic data presented across four days. - Ocular Therapeutix reported phase 3 SOL-1 results showing a single AXPAXLI injection maintained BCVA in 74.1% of patients at Week 36 versus 55.8% with monthly aflibercept. - Nanoscope Therapeutics presented 3-year REMAIN data showing durable BCVA gains of about 3 ETDRS lines with MCO-010 in retinitis pigmentosa, alongside a rolling BLA submission. - Belite Bio's phase 3 DRAGON trial of oral tinlarebant met its primary endpoint with a 36% reduction in retinal lesion growth versus placebo in Stargardt disease.
- Sangamo Therapeutics, a three-decade-old gene editing pioneer, filed for Chapter 11 bankruptcy with $115 million in debt and just $5.5 million in cash remaining. - Eli Lilly has offered $50 million for Sangamo's core gene editing platforms and an experimental prion disease treatment, while Astellas bid up to $50 million for a Fabry disease gene therapy nearing regulatory approval. - The company's partnership model collapsed after Novartis, Biogen, and Pfizer terminated major collaborations, causing revenues to plummet from $176.2 million in 2023 to $39.6 million in 2025. - A court-supervised auction is scheduled for next month, with 77 employees retained specifically for the asset purchases by Lilly and Astellas.
- The global oligonucleotide synthesis market was valued at USD 2.8 billion in 2025 and is projected to reach USD 8.6 billion by 2035, growing at a CAGR of 12.5%. - Thermo Fisher Scientific leads the market with a 15.2% share, while the top five players collectively hold approximately 55% of total revenue. - The therapeutics application segment is expected to grow at the highest CAGR of 13.25%, fueled by over 100 active nucleic acid therapeutic clinical trials and 24 FDA-approved oligonucleotide drugs. - North America remains the largest regional market, while Asia Pacific is the fastest-growing region, driven by expanding biotechnology infrastructure in China, India, and South Korea.
- Johnson & Johnson has agreed to acquire Firefly Bio for $1 billion in an all-cash deal, gaining access to its proprietary Firelink degrader-antibody conjugate (DAC) platform. - The Firelink platform is designed to deliver highly selective protein degraders to KRAS-driven tumor cells while sparing healthy tissue, addressing a notoriously undruggable target. - KRAS mutations occur in nearly a quarter of all human cancers, and patients with KRAS-driven cancers currently face limited treatment options with survival measured in months. - The acquisition, expected to close before the end of 2026 pending regulatory approvals, diversifies J&J's oncology pipeline with preclinical candidates for multiple solid tumor types.
- The Dry Age-Related Macular Degeneration market across the 7MM is projected to grow at a 19.2% CAGR through 2036, driven by novel therapies and rising disease prevalence exceeding 72 million AMD cases in 2025. - Emerging oral therapies like Tinlarebant and Gildeuretinol acetate target vitamin A–driven retinal toxicity, offering alternatives to chronic intravitreal injections required by approved complement inhibitors IZERVAY and SYFOVRE. - Ocugen reported a statistically significant 31% reduction in GA lesion growth in its Phase II ArMaDa trial for gene therapy OCU410, with Phase III initiation planned for Q3 2026. - Gene therapies and regenerative medicine candidates, including Eyestem's recently approved Phase II cell therapy Eyecyte-RPE, are attracting substantial industry interest for their potential one-time administration benefit.
- More than 30% of clinical trials globally experience delays due to data quality issues, costing pharmaceutical companies billions and delaying patient access to life-saving therapies. - Ramakrishna Sesham developed enterprise clinical data governance frameworks that connect research systems directly to regulatory requirements, enabling submission-ready outputs immediately after trial completion. - His systems at Spectrum Pharmaceuticals supported FDA approval of ROLONTIS for chemotherapy-induced neutropenia, while his current work at Astellas Pharma manages regulatory submissions for oncology and rare disease programs affecting millions of patients. - The risk-based quality frameworks identify compliance issues during trial design rather than after data collection, significantly compressing drug development timelines.
